Recruiting
Yervoy Pregnancy Surveillance Study - CA184-487
Zaktualizowano:
15 luty, 2018
|
ClinicalTrials.gov
Płeć
Zakres wieku
Lokalizacje
Recruiting
Inclusion Criteria: - Documented exposure to Yervoy while pregnant or within 90 days of discontinuing treatment Exclusion Criteria: - Women whose ipilimumab exposure is outside the window of pregnancy exposure - Pregnancies for which there is only paternal exposure to Yervoy Other protocol defined inclusion/exclusion criteria could apply